| Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation E Legius, L Messiaen, P Wolkenstein, P Pancza, RA Avery, Y Berman, ... Genetics in Medicine 23 (8), 1506-1513, 2021 | 386 | 2021 |
| Song‐selective auditory input to a forebrain vocal control nucleus in the zebra finch DS Vicario, KH Yohay Journal of neurobiology 24 (4), 488-505, 1993 | 167 | 1993 |
| Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) DR Stewart, BR Korf, KL Nathanson, DA Stevenson, K Yohay Genetics in Medicine 20 (7), 671-682, 2018 | 155 | 2018 |
| The life span of new neurons in a song control nucleus of the adult canary brain depends on time of year when these cells are born. F Nottebohm, B O'loughlin, K Gould, K Yohay, A Alvarez-Buylla Proceedings of the National Academy of Sciences 91 (17), 7849-7853, 1994 | 113 | 1994 |
| Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study M Nickel, A Simonati, D Jacoby, S Lezius, D Kilian, B Van de Graaf, ... The Lancet Child & Adolescent Health 2 (8), 582-590, 2018 | 110 | 2018 |
| Clinical spectrum of individuals with pathogenic NF1 missense variants affecting p.Met1149, p.Arg1276, and p.Lys1423: genotype–phenotype study in … M Koczkowska, T Callens, Y Chen, A Gomes, AD Hicks, A Sharp, E Johns, ... Human mutation 41 (1), 299-315, 2020 | 109 | 2020 |
| The genetic and molecular pathogenesis of NF1 and NF2 KH Yohay Seminars in pediatric neurology 13 (1), 21-26, 2006 | 109 | 2006 |
| Inverse correlation between cerebral blood flow measured by continuous arterial spin-labeling (CASL) MRI and neurocognitive function in children with sickle cell anemia (SCA) JJ Strouse, CS Cox, ER Melhem, H Lu, MA Kraut, A Razumovsky, ... Blood 108 (1), 379-381, 2006 | 104 | 2006 |
| Long-term expression and safety of administration of AAVrh. 10hCLN2 to the brain of rats and nonhuman primates for the treatment of late infantile neuronal ceroid lipofuscinosis D Sondhi, L Johnson, K Purpura, S Monette, MM Souweidane, MG Kaplitt, ... Human Gene Therapy, Part B: Methods 23 (5), 324-335, 2012 | 103 | 2012 |
| Neurofibromatosis types 1 and 2 K Yohay The neurologist 12 (2), 86-93, 2006 | 94 | 2006 |
| Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2 DG Evans, M Kalamarides, K Hunter-Schaedle, J Blakeley, J Allen, ... Clinical cancer research 15 (16), 5032-5039, 2009 | 93 | 2009 |
| Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation SR Plotkin, L Messiaen, E Legius, P Pancza, RA Avery, JO Blakeley, ... Genetics in Medicine 24 (9), 1967-1977, 2022 | 85 | 2022 |
| Neurofibromatosis type 1 and associated malignancies K Yohay Current neurology and neuroscience reports 9 (3), 247-253, 2009 | 76 | 2009 |
| The use of MEK inhibitors in neurofibromatosis type 1–associated tumors and management of toxicities LJ Klesse, JT Jordan, HB Radtke, T Rosser, E Schorry, N Ullrich, ... The oncologist 25 (7), e1109-e1116, 2020 | 65 | 2020 |
| Offense produced by chemical stimulation of the anterior hypothalamus of the rat DB Adams, W Boudreau, CW Cowan, C Kokonowski, K Oberteuffer, ... Physiology & behavior 53 (6), 1127-1132, 1993 | 49 | 1993 |
| Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function A Orlin, D Sondhi, MT Witmer, MM Wessel, JG Mezey, SM Kaminsky, ... PLoS One 8 (8), e73128, 2013 | 44 | 2013 |
| Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2 D Sondhi, SM Kaminsky, NR Hackett, OE Pagovich, JB Rosenberg, ... Science translational medicine 12 (572), eabb5413, 2020 | 42 | 2020 |
| Management of neurofibromatosis type 1-associated plexiform neurofibromas MJ Fisher, JO Blakeley, BD Weiss, E Dombi, S Ahlawat, S Akshintala, ... Neuro-oncology 24 (11), 1827-1844, 2022 | 41 | 2022 |
| MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus PMK De Blank, AM Gross, S Akshintala, JO Blakeley, G Bollag, A Cannon, ... Neuro-oncology 24 (11), 1845-1856, 2022 | 37 | 2022 |
| International Consensus Group on Neurofibromatosis Diagnostic Criteria (I-NF-DC). Huson SM, Evans DG, Plotkin SR. Revised diagnostic criteria for neurofibromatosis type 1 and … E Legius, L Messiaen, P Wolkenstein, P Pancza, RA Avery, Y Berman, ... Genet Med 23 (8), 1506-1513, 2021 | 36 | 2021 |
